Luisa Stamm has joined Assembly Biosciences (NASDAQ: [[ticker:ASMB]]) as chief medical officer. Stamm comes to South San Francisco-based Assembly from Gilead Siences (NASDAQ: [[ticker:GILD]]), where she was executive director in the liver diseases therapeutic area, as well as executive director in the HIV and emerging viruses therapeutic area. Assembly is developing drugs for hepatitis B virus and diseases associated with the microbiome.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
